S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
Here's something only a handful of people know (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Here's something only a handful of people know (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
Here's something only a handful of people know (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Here's something only a handful of people know (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
Here's something only a handful of people know (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Here's something only a handful of people know (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
BJ's Restaurants' Approaching Buy Point As Earnings Surge 150%
66,000% upside on tiny biotech? (Ad)
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
Will NIO Partake In China's Economic Awakening?
Here's something only a handful of people know (Ad)
How to Choose a Brokerage Account or Online Broker
Tax Software Specialist Vertex In Buy Zone After Base Breakout
Here's something only a handful of people know (Ad)
What is a Mutual Fund? How Does it Work?
Will Plug Power’s Deal With Energy Vault Move The Needle? 
NYSE:PKI

Revvity (PKI) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
$115.24
▼
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
$158.60
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Revvity MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
∞ Upside
$158.60 Price Target
Short Interest
Bearish
2.79% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.45mentions of Revvity in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth
17.71%
From $4.97 to $5.85 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.95 out of 5 stars

Medical Sector

23rd out of 988 stocks

Analytical Instruments Industry

2nd out of 28 stocks

See Top Rated MarketRank™ Stocks Here

PKI stock logo

About Revvity (NYSE:PKI) Stock

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

June 4, 2023 | americanbankingnews.com
Revvity (NYSE:PKI) Now Covered by Analysts at StockNews.com
June 2, 2023 | americanbankingnews.com
Brokerages Set Revvity, Inc. (NYSE:PKI) Target Price at $158.60
June 10, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 27, 2023 | americanbankingnews.com
Revvity (NYSE:PKI) Receives New Coverage from Analysts at StockNews.com
May 19, 2023 | finance.yahoo.com
PerkinElmer Completes Transformation to Become Revvity
May 18, 2023 | finance.yahoo.com
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
May 16, 2023 | markets.businessinsider.com
J.P. Morgan Keeps Their Hold Rating on PerkinElmer (PKI)
May 16, 2023 | americanbankingnews.com
KeyCorp Comments on PerkinElmer, Inc.'s Q3 2023 Earnings (NYSE:PKI)
June 10, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 15, 2023 | msn.com
Citigroup Maintains Revvity (PKI) Buy Recommendation
May 15, 2023 | markets.businessinsider.com
Analyst Ratings for Revvity
May 15, 2023 | markets.businessinsider.com
PerkinElmer (PKI) Receives a Buy from Citigroup
May 15, 2023 | americanbankingnews.com
Citigroup Cuts PerkinElmer (NYSE:PKI) Price Target to $160.00
May 15, 2023 | americanbankingnews.com
Robert W. Baird Cuts PerkinElmer (NYSE:PKI) Price Target to $165.00
May 15, 2023 | americanbankingnews.com
Stifel Nicolaus Trims PerkinElmer (NYSE:PKI) Target Price to $135.00
May 14, 2023 | americanbankingnews.com
PerkinElmer (NYSE:PKI) Price Target Cut to $125.00
May 13, 2023 | americanbankingnews.com
PerkinElmer (NYSE:PKI) Releases Earnings Results, Misses Estimates By $0.06 EPS
May 13, 2023 | msn.com
Barclays Maintains Perkinelmer (PKI) Equal-Weight Recommendation
May 13, 2023 | americanbankingnews.com
PerkinElmer (NYSE:PKI) Shares Gap Down Following Weak Earnings
May 12, 2023 | msn.com
Stifel Maintains Perkinelmer (PKI) Hold Recommendation
May 12, 2023 | msn.com
Baird Maintains Perkinelmer (PKI) Outperform Recommendation
May 12, 2023 | markets.businessinsider.com
Barclays Keeps Their Hold Rating on PerkinElmer (PKI)
May 12, 2023 | markets.businessinsider.com
PerkinElmer (PKI) Gets a Hold from Stifel Nicolaus
May 11, 2023 | seekingalpha.com
Revvity, Inc. 2023 Q1 - Results - Earnings Call Presentation
May 11, 2023 | markets.businessinsider.com
Revvity, Inc. Reveals Increase In Q1 Profit
May 11, 2023 | markets.businessinsider.com
Revvity Now Sees FY23 Results Below View; To Buy Back $600 Mln Of Shares
May 11, 2023 | finance.yahoo.com
Revvity Announces Financial Results for the First Quarter of 2023
See More Headlines


PKI Company Calendar

Ex-Dividend for 5/12 Dividend
4/20/2023
Last Earnings
5/11/2023
Dividend Payable
5/12/2023
Today
6/09/2023
Next Earnings (Estimated)
8/07/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NYSE:PKI
CUSIP
71404610
CIK
31791
Web
www.perkinelmer.com
Phone
(781) 663-6900
Fax
781-663-5985
Employees
16,700
Year Founded
1937

Price Target and Rating

Average Stock Price Forecast
$158.60
High Stock Price Forecast
$178.00
Low Stock Price Forecast
$125.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$7.68
Trailing P/E Ratio
15.01
Forward P/E Ratio
N/A
P/E Growth
0.5
Net Income
$569.18 million
Net Margins
28.94%
Pretax Margin
13.81%
Return on Equity
11.17%
Return on Assets
5.83%

Debt

Debt-to-Equity Ratio
0.48
Current Ratio
2.43
Quick Ratio
2.15

Sales & Book Value

Annual Sales
$3.31 billion
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
9.88
Book Value
$58.49 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
126,410,000
Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links


Key Executives

  • Prahlad Ramadhar Singh
    President, Chief Executive Officer & Director
  • Tajinder S. Vohra
    Senior Vice President-Global Operations
  • Maxwell Krakowiak
    Chief Financial Officer & Senior Vice President
  • Yi Ping Lin
    Chief Quality, Regulatory & Clinical Officer
  • Jayashree Kailas Thacker
    Chief Information Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PKI Stock - Frequently Asked Questions

Should I buy or sell Revvity stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revvity in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PKI shares.
View PKI analyst ratings or view top-rated stocks.

What is Revvity's stock price forecast for 2023?

10 equities research analysts have issued 1 year price objectives for Revvity's shares. Their PKI share price forecasts range from $125.00 to $178.00. On average, they anticipate the company's stock price to reach $158.60 in the next twelve months.
View analysts price targets for PKI or view top-rated stocks among Wall Street analysts.

When is Revvity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our PKI earnings forecast.

How were Revvity's earnings last quarter?

Revvity, Inc. (NYSE:PKI) released its earnings results on Thursday, May, 11th. The medical research company reported $1.01 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to the consensus estimate of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%. During the same period in the previous year, the business posted $2.41 earnings per share.

How often does Revvity pay dividends? What is the dividend yield for Revvity?

Revvity declared a quarterly dividend on Tuesday, April 25th. Stockholders of record on Friday, July 21st will be paid a dividend of $0.07 per share on Friday, August 11th. This represents a $0.28 annualized dividend and a dividend yield of ∞. The ex-dividend date is Thursday, July 20th.
Read our dividend analysis for PKI.

What ETFs hold Revvity's stock?

ETFs with the largest weight of Revvity (NYSE:PKI) stock in their portfolio include AXS Cannabis ETF (THCX), Simplify Health Care ETF (PINK), WisdomTree BioRevolution Fund (WDNA), First Trust Indxx Medical Devices ETF (MDEV), Janus Henderson US Sustainable Equity ETF (SSPX), Franklin Genomic Advancements ETF (HELX), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Is Revvity a good dividend stock?

Revvity (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.24%. The dividend payout ratio is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.79% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.

What guidance has Revvity issued on next quarter's earnings?

Revvity issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $4.85-$5.05 for the period, compared to the consensus estimate of $5.16. The company issued revenue guidance of $2.90 billion-$2.94 billion, compared to the consensus revenue estimate of $3.15 billion.

What is Prahlad Singh's approval rating as Revvity's CEO?

27 employees have rated Revvity Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.

What other stocks do shareholders of Revvity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revvity investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is Revvity's stock symbol?

Revvity trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are Revvity's major shareholders?

Revvity's stock is owned by many different institutional and retail investors. Top institutional shareholders include Select Equity Group L.P. (7.86%), BlackRock Inc. (6.79%), State Street Corp (4.10%), Geode Capital Management LLC (2.06%), Pictet Asset Management SA (1.59%) and Ceredex Value Advisors LLC (0.77%). Insiders that own company stock include Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Maxwell Krakowiak, Prahlad R Singh, Sylvie Gregoire and Tajinder S Vohra.
View institutional ownership trends.

How do I buy shares of Revvity?

Shares of PKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Revvity make?

Revvity (NYSE:PKI) has a market capitalization of $0.00 and generates $3.31 billion in revenue each year. The medical research company earns $569.18 million in net income (profit) each year or $7.68 on an earnings per share basis.

How many employees does Revvity have?

The company employs 16,700 workers across the globe.

Does Revvity have any subsidiaries?
The following companies are subsidiares of Revvity: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More
How can I contact Revvity?

Revvity's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -